
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, announced that it has submitted an Investigational New …
Read More